Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects
Xconomy
MARCH 5, 2020
A 20-patient Phase 1 study of an RNA drug discovered by Ionis Pharmaceuticals that is being tested as a treatment for Huntington’s disease by Roche was suspended after two reports of infections related to a device used to take samples of cerebral spinal fluid during the trial.
Let's personalize your content